nodes	percent_of_prediction	percent_of_DWPC	metapath
Capreomycin—Nephritis—Erlotinib—pancreatic cancer	0.0553	0.0553	CcSEcCtD
Capreomycin—Ototoxicity—Docetaxel—pancreatic cancer	0.0464	0.0464	CcSEcCtD
Capreomycin—Foetor hepaticus—Erlotinib—pancreatic cancer	0.0333	0.0333	CcSEcCtD
Capreomycin—Liver disorder—Erlotinib—pancreatic cancer	0.0277	0.0277	CcSEcCtD
Capreomycin—Injection site haemorrhage—Epirubicin—pancreatic cancer	0.0233	0.0233	CcSEcCtD
Capreomycin—Nephropathy toxic—Gemcitabine—pancreatic cancer	0.0229	0.0229	CcSEcCtD
Capreomycin—Injection site haemorrhage—Doxorubicin—pancreatic cancer	0.0216	0.0216	CcSEcCtD
Capreomycin—Hypomagnesaemia—Irinotecan—pancreatic cancer	0.0212	0.0212	CcSEcCtD
Capreomycin—Abscess—Sunitinib—pancreatic cancer	0.0207	0.0207	CcSEcCtD
Capreomycin—Hypomagnesaemia—Gemcitabine—pancreatic cancer	0.0207	0.0207	CcSEcCtD
Capreomycin—Hepatocellular injury—Tamoxifen—pancreatic cancer	0.0191	0.0191	CcSEcCtD
Capreomycin—Hepatocellular injury—Erlotinib—pancreatic cancer	0.0189	0.0189	CcSEcCtD
Capreomycin—Hypocalcaemia—Sunitinib—pancreatic cancer	0.0179	0.0179	CcSEcCtD
Capreomycin—Foetor hepaticus—Docetaxel—pancreatic cancer	0.0164	0.0164	CcSEcCtD
Capreomycin—Renal impairment—Erlotinib—pancreatic cancer	0.0144	0.0144	CcSEcCtD
Capreomycin—Hypocalcaemia—Gemcitabine—pancreatic cancer	0.0143	0.0143	CcSEcCtD
Capreomycin—Hearing impaired—Gemcitabine—pancreatic cancer	0.0138	0.0138	CcSEcCtD
Capreomycin—Leukocytosis—Fluorouracil—pancreatic cancer	0.0137	0.0137	CcSEcCtD
Capreomycin—Liver disorder—Docetaxel—pancreatic cancer	0.0137	0.0137	CcSEcCtD
Capreomycin—Hypokalaemia—Erlotinib—pancreatic cancer	0.0125	0.0125	CcSEcCtD
Capreomycin—Renal impairment—Sunitinib—pancreatic cancer	0.0125	0.0125	CcSEcCtD
Capreomycin—Urine abnormality—Epirubicin—pancreatic cancer	0.0114	0.0114	CcSEcCtD
Capreomycin—Hypokalaemia—Sunitinib—pancreatic cancer	0.0108	0.0108	CcSEcCtD
Capreomycin—Urine analysis abnormal—Epirubicin—pancreatic cancer	0.0107	0.0107	CcSEcCtD
Capreomycin—Deafness—Gemcitabine—pancreatic cancer	0.0107	0.0107	CcSEcCtD
Capreomycin—Urine abnormality—Doxorubicin—pancreatic cancer	0.0105	0.0105	CcSEcCtD
Capreomycin—Renal failure—Erlotinib—pancreatic cancer	0.0104	0.0104	CcSEcCtD
Capreomycin—Renal impairment—Irinotecan—pancreatic cancer	0.0103	0.0103	CcSEcCtD
Capreomycin—Oliguria—Docetaxel—pancreatic cancer	0.0101	0.0101	CcSEcCtD
Capreomycin—Renal impairment—Gemcitabine—pancreatic cancer	0.01	0.01	CcSEcCtD
Capreomycin—Hypomagnesaemia—Epirubicin—pancreatic cancer	0.0099	0.0099	CcSEcCtD
Capreomycin—Urine analysis abnormal—Doxorubicin—pancreatic cancer	0.00989	0.00989	CcSEcCtD
Capreomycin—Hearing impaired—Docetaxel—pancreatic cancer	0.00979	0.00979	CcSEcCtD
Capreomycin—Hepatocellular injury—Docetaxel—pancreatic cancer	0.00932	0.00932	CcSEcCtD
Capreomycin—Hypomagnesaemia—Doxorubicin—pancreatic cancer	0.00916	0.00916	CcSEcCtD
Capreomycin—Renal failure—Sunitinib—pancreatic cancer	0.009	0.009	CcSEcCtD
Capreomycin—Hypokalaemia—Irinotecan—pancreatic cancer	0.00891	0.00891	CcSEcCtD
Capreomycin—Hypokalaemia—Gemcitabine—pancreatic cancer	0.00868	0.00868	CcSEcCtD
Capreomycin—Eosinophilia—Fluorouracil—pancreatic cancer	0.00802	0.00802	CcSEcCtD
Capreomycin—Abscess—Epirubicin—pancreatic cancer	0.00795	0.00795	CcSEcCtD
Capreomycin—Deafness—Docetaxel—pancreatic cancer	0.00756	0.00756	CcSEcCtD
Capreomycin—Leukopenia—Tamoxifen—pancreatic cancer	0.00748	0.00748	CcSEcCtD
Capreomycin—Renal failure—Irinotecan—pancreatic cancer	0.00741	0.00741	CcSEcCtD
Capreomycin—Abscess—Doxorubicin—pancreatic cancer	0.00735	0.00735	CcSEcCtD
Capreomycin—Renal failure—Gemcitabine—pancreatic cancer	0.00722	0.00722	CcSEcCtD
Capreomycin—Renal impairment—Docetaxel—pancreatic cancer	0.00711	0.00711	CcSEcCtD
Capreomycin—Hypocalcaemia—Epirubicin—pancreatic cancer	0.00687	0.00687	CcSEcCtD
Capreomycin—Oliguria—Epirubicin—pancreatic cancer	0.00682	0.00682	CcSEcCtD
Capreomycin—Thrombocytopenia—Tamoxifen—pancreatic cancer	0.00668	0.00668	CcSEcCtD
Capreomycin—Thrombocytopenia—Erlotinib—pancreatic cancer	0.00661	0.00661	CcSEcCtD
Capreomycin—Leukopenia—Sunitinib—pancreatic cancer	0.00641	0.00641	CcSEcCtD
Capreomycin—Hypocalcaemia—Doxorubicin—pancreatic cancer	0.00635	0.00635	CcSEcCtD
Capreomycin—Oliguria—Doxorubicin—pancreatic cancer	0.00631	0.00631	CcSEcCtD
Capreomycin—Hepatocellular injury—Epirubicin—pancreatic cancer	0.00629	0.00629	CcSEcCtD
Capreomycin—Pain—Tamoxifen—pancreatic cancer	0.00583	0.00583	CcSEcCtD
Capreomycin—Hepatocellular injury—Doxorubicin—pancreatic cancer	0.00582	0.00582	CcSEcCtD
Capreomycin—Pain—Erlotinib—pancreatic cancer	0.00577	0.00577	CcSEcCtD
Capreomycin—Thrombocytopenia—Sunitinib—pancreatic cancer	0.00572	0.00572	CcSEcCtD
Capreomycin—Urticaria—Tamoxifen—pancreatic cancer	0.00542	0.00542	CcSEcCtD
Capreomycin—Body temperature increased—Erlotinib—pancreatic cancer	0.00533	0.00533	CcSEcCtD
Capreomycin—Vertigo—Irinotecan—pancreatic cancer	0.0053	0.0053	CcSEcCtD
Capreomycin—Leukopenia—Irinotecan—pancreatic cancer	0.00528	0.00528	CcSEcCtD
Capreomycin—Leukopenia—Gemcitabine—pancreatic cancer	0.00514	0.00514	CcSEcCtD
Capreomycin—Renal failure—Docetaxel—pancreatic cancer	0.00513	0.00513	CcSEcCtD
Capreomycin—Leukopenia—Fluorouracil—pancreatic cancer	0.00505	0.00505	CcSEcCtD
Capreomycin—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00502	0.00502	CcSEcCtD
Capreomycin—Pain—Sunitinib—pancreatic cancer	0.00499	0.00499	CcSEcCtD
Capreomycin—Renal impairment—Epirubicin—pancreatic cancer	0.0048	0.0048	CcSEcCtD
Capreomycin—Thrombocytopenia—Irinotecan—pancreatic cancer	0.00471	0.00471	CcSEcCtD
Capreomycin—Body temperature increased—Sunitinib—pancreatic cancer	0.00462	0.00462	CcSEcCtD
Capreomycin—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.00459	0.00459	CcSEcCtD
Capreomycin—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.00451	0.00451	CcSEcCtD
Capreomycin—Renal impairment—Doxorubicin—pancreatic cancer	0.00444	0.00444	CcSEcCtD
Capreomycin—Hypersensitivity—Sunitinib—pancreatic cancer	0.0043	0.0043	CcSEcCtD
Capreomycin—Rash—Tamoxifen—pancreatic cancer	0.0043	0.0043	CcSEcCtD
Capreomycin—Dermatitis—Tamoxifen—pancreatic cancer	0.0043	0.0043	CcSEcCtD
Capreomycin—Rash—Erlotinib—pancreatic cancer	0.00425	0.00425	CcSEcCtD
Capreomycin—Dermatitis—Erlotinib—pancreatic cancer	0.00425	0.00425	CcSEcCtD
Capreomycin—Hypokalaemia—Epirubicin—pancreatic cancer	0.00415	0.00415	CcSEcCtD
Capreomycin—Pain—Irinotecan—pancreatic cancer	0.00411	0.00411	CcSEcCtD
Capreomycin—Pain—Gemcitabine—pancreatic cancer	0.00401	0.00401	CcSEcCtD
Capreomycin—Pain—Fluorouracil—pancreatic cancer	0.00394	0.00394	CcSEcCtD
Capreomycin—Eosinophilia—Epirubicin—pancreatic cancer	0.00391	0.00391	CcSEcCtD
Capreomycin—Hypokalaemia—Doxorubicin—pancreatic cancer	0.00384	0.00384	CcSEcCtD
Capreomycin—Body temperature increased—Irinotecan—pancreatic cancer	0.0038	0.0038	CcSEcCtD
Capreomycin—Body temperature increased—Gemcitabine—pancreatic cancer	0.0037	0.0037	CcSEcCtD
Capreomycin—Rash—Sunitinib—pancreatic cancer	0.00368	0.00368	CcSEcCtD
Capreomycin—Dermatitis—Sunitinib—pancreatic cancer	0.00368	0.00368	CcSEcCtD
Capreomycin—Urticaria—Fluorouracil—pancreatic cancer	0.00366	0.00366	CcSEcCtD
Capreomycin—Leukopenia—Docetaxel—pancreatic cancer	0.00365	0.00365	CcSEcCtD
Capreomycin—Body temperature increased—Fluorouracil—pancreatic cancer	0.00364	0.00364	CcSEcCtD
Capreomycin—Eosinophilia—Doxorubicin—pancreatic cancer	0.00361	0.00361	CcSEcCtD
Capreomycin—Hypersensitivity—Irinotecan—pancreatic cancer	0.00354	0.00354	CcSEcCtD
Capreomycin—Renal failure—Epirubicin—pancreatic cancer	0.00346	0.00346	CcSEcCtD
Capreomycin—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00339	0.00339	CcSEcCtD
Capreomycin—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00326	0.00326	CcSEcCtD
Capreomycin—Renal failure—Doxorubicin—pancreatic cancer	0.0032	0.0032	CcSEcCtD
Capreomycin—Rash—Irinotecan—pancreatic cancer	0.00303	0.00303	CcSEcCtD
Capreomycin—Dermatitis—Irinotecan—pancreatic cancer	0.00303	0.00303	CcSEcCtD
Capreomycin—Rash—Gemcitabine—pancreatic cancer	0.00295	0.00295	CcSEcCtD
Capreomycin—Dermatitis—Gemcitabine—pancreatic cancer	0.00295	0.00295	CcSEcCtD
Capreomycin—Tinnitus—Epirubicin—pancreatic cancer	0.00294	0.00294	CcSEcCtD
Capreomycin—Rash—Fluorouracil—pancreatic cancer	0.00291	0.00291	CcSEcCtD
Capreomycin—Dermatitis—Fluorouracil—pancreatic cancer	0.0029	0.0029	CcSEcCtD
Capreomycin—Pain—Docetaxel—pancreatic cancer	0.00284	0.00284	CcSEcCtD
Capreomycin—Tinnitus—Doxorubicin—pancreatic cancer	0.00272	0.00272	CcSEcCtD
Capreomycin—Body temperature increased—Docetaxel—pancreatic cancer	0.00263	0.00263	CcSEcCtD
Capreomycin—Vertigo—Epirubicin—pancreatic cancer	0.00247	0.00247	CcSEcCtD
Capreomycin—Leukopenia—Epirubicin—pancreatic cancer	0.00246	0.00246	CcSEcCtD
Capreomycin—Hypersensitivity—Docetaxel—pancreatic cancer	0.00245	0.00245	CcSEcCtD
Capreomycin—Vertigo—Doxorubicin—pancreatic cancer	0.00228	0.00228	CcSEcCtD
Capreomycin—Leukopenia—Doxorubicin—pancreatic cancer	0.00228	0.00228	CcSEcCtD
Capreomycin—Thrombocytopenia—Epirubicin—pancreatic cancer	0.0022	0.0022	CcSEcCtD
Capreomycin—Rash—Docetaxel—pancreatic cancer	0.0021	0.0021	CcSEcCtD
Capreomycin—Dermatitis—Docetaxel—pancreatic cancer	0.00209	0.00209	CcSEcCtD
Capreomycin—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.00203	0.00203	CcSEcCtD
Capreomycin—Pain—Epirubicin—pancreatic cancer	0.00192	0.00192	CcSEcCtD
Capreomycin—Urticaria—Epirubicin—pancreatic cancer	0.00178	0.00178	CcSEcCtD
Capreomycin—Pain—Doxorubicin—pancreatic cancer	0.00177	0.00177	CcSEcCtD
Capreomycin—Body temperature increased—Epirubicin—pancreatic cancer	0.00177	0.00177	CcSEcCtD
Capreomycin—Hypersensitivity—Epirubicin—pancreatic cancer	0.00165	0.00165	CcSEcCtD
Capreomycin—Urticaria—Doxorubicin—pancreatic cancer	0.00165	0.00165	CcSEcCtD
Capreomycin—Body temperature increased—Doxorubicin—pancreatic cancer	0.00164	0.00164	CcSEcCtD
Capreomycin—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00153	0.00153	CcSEcCtD
Capreomycin—Rash—Epirubicin—pancreatic cancer	0.00141	0.00141	CcSEcCtD
Capreomycin—Dermatitis—Epirubicin—pancreatic cancer	0.00141	0.00141	CcSEcCtD
Capreomycin—Rash—Doxorubicin—pancreatic cancer	0.00131	0.00131	CcSEcCtD
Capreomycin—Dermatitis—Doxorubicin—pancreatic cancer	0.00131	0.00131	CcSEcCtD
